Literature DB >> 30363393

Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.

Tiago A Mestre1, Maria João Forjaz2, Philipp Mahlknecht3, Francisco Cardoso4, Joaquim J Ferreira5, Ralf Reilmann6, Cristina Sampaio7, Christopher G Goetz8, Esther Cubo9, Pablo Martinez-Martin10, Glenn T Stebbins8.   

Abstract

Motor symptoms are a major feature of Huntington's disease (HD). The International Parkinson and Movement Disorder Society (MDS) commissioned the assessment of the clinimetric properties of motor rating scales in HD to make recommendations regarding their use, following previously established standardized criteria. After a systematic literature search, a total of 6 rating scales assessing motor symptoms and signs in HD were included for review. Performance testing (reviewed elsewhere) and quantitative motor rating methods were excluded. Only the Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) was classified as "recommended" for assessing the severity of motor signs in HD. The following scales were classified as "suggested": Abnormal Involuntary Movement Scale, the UHDRS-TMS4, the Quantified Neurological Examination, and the Marsden and Quinn Chorea Severity Scale. The committee also concluded that further assessment of existing rating scales, including the UHDRS-TMS, is necessary to determine sensitivity to change and to screening for the presence of motor signs specific to HD. There is also a need to develop a motor rating scale to be used in positive gene carriers with subtle but not definite motor signs.

Entities:  

Keywords:  Chorea; Clinimetrics; Dyskinesia; Huntington's disease; Motor; Parkinsonism; rating scales; validation

Year:  2018        PMID: 30363393      PMCID: PMC6174417          DOI: 10.1002/mdc3.12571

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  37 in total

1.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.

Authors: 
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

Review 3.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

4.  Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.

Authors:  B Kremer; C M Clark; E W Almqvist; L A Raymond; P Graf; C Jacova; M Mezei; M A Hardy; B Snow; W Martin; M R Hayden
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

5.  Reliability and clinical utility of a Portuguese version of the Abnormal Involuntary Movements Scale (AIMS) for tardive dyskinesia in Brazilian patients.

Authors:  H Tonelli; D Tonelli; G R Poiani; M A B F Vital; R Andreatini
Journal:  Braz J Med Biol Res       Date:  2003-04-08       Impact factor: 2.590

6.  Effect of donepezil on motor and cognitive function in Huntington disease.

Authors:  E Cubo; K M Shannon; D Tracy; J A Jaglin; B A Bernard; J Wuu; S E Leurgans
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

7.  A shortened version of the motor section of the Unified Huntington's Disease Rating Scale.

Authors:  S Siesling; A H Zwinderman; J P van Vugt; K Kieburtz; R A Roos
Journal:  Mov Disord       Date:  1997-03       Impact factor: 10.338

Review 8.  Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.

Authors:  Carlo Colosimo; Pablo Martínez-Martín; Giovanni Fabbrini; Robert A Hauser; Marcelo Merello; Janis Miyasaki; Werner Poewe; Cristina Sampaio; Olivier Rascol; Glenn T Stebbins; Anette Schrag; Christopher G Goetz
Journal:  Mov Disord       Date:  2010-07-15       Impact factor: 10.338

9.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2013-05-09       Impact factor: 44.182

10.  Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.

Authors:  Joaquim J Ferreira; Anne Rosser; David Craufurd; Ferdinando Squitieri; Nicholas Mallard; Bernhard Landwehrmeyer
Journal:  Mov Disord       Date:  2015-07-14       Impact factor: 10.338

View more
  7 in total

1.  The risks of converting post-hoc findings into primary outcomes in subsequent trials.

Authors:  Filipe B Rodrigues; Joaquim J Ferreira
Journal:  Ann Transl Med       Date:  2019-12

2.  Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.

Authors:  Filipe B Rodrigues; Lauren M Byrne; Rosanna Tortelli; Eileanoir B Johnson; Peter A Wijeratne; Marzena Arridge; Enrico De Vita; Naghmeh Ghazaleh; Richard Houghton; Hannah Furby; Daniel C Alexander; Sarah J Tabrizi; Scott Schobel; Rachael I Scahill; Amanda Heslegrave; Henrik Zetterberg; Edward J Wild
Journal:  Sci Transl Med       Date:  2020-12-16       Impact factor: 17.956

3.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

4.  Objectively characterizing Huntington's disease using a novel upper limb dexterity test.

Authors:  Samuel Woodgate; Philippa Morgan-Jones; Susanne Clinch; Cheney Drew; Rebecca Playle; Mohamed Bennasar; Yulia Hicks; Catherine Holt; Anne-Catherine Bachoud-Lévi; Renaud Massart; David Craufurd; Nigel Kirby; Katy Hamana; Robin Schubert; Ralf Reilmann; Anne Rosser; Monica Busse
Journal:  J Neurol       Date:  2021-02-08       Impact factor: 4.849

5.  The use of wearable/portable digital sensors in Huntington's disease: A systematic review.

Authors:  Rosanna Tortelli; Filipe B Rodrigues; Edward J Wild
Journal:  Parkinsonism Relat Disord       Date:  2021-01-12       Impact factor: 4.891

Review 6.  Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules.

Authors:  Hidetoshi Komatsu
Journal:  Front Cell Neurosci       Date:  2021-11-26       Impact factor: 5.505

7.  Predicting Severity of Huntington's Disease With Wearable Sensors.

Authors:  Brittany H Scheid; Stephen Aradi; Robert M Pierson; Steven Baldassano; Inbar Tivon; Brian Litt; Pedro Gonzalez-Alegre
Journal:  Front Digit Health       Date:  2022-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.